Screener
Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $364.25M+71.2% | $311.34M+127% | $321.08M+211% | $287.27M+362% | $212.8M+1,354% | ||
| —— | —— | —— | —— | —— | ||
| $91.18M+68.6% | $108.69M+146% | $116.27M+353% | $174M+153% | $54.08M-23.9% | ||
| $289.38M+47.0% | $268.52M+60.0% | $239.98M+69.9% | $209.12M+94.4% | $196.86M+86.7% | ||
| $420.56M+61.8% | $404.06M+86.6% | $380.69M+124% | $401.24M+125% | $260M+46.7% | ||
| $40.01M+341% | $26.85M+495% | $24.45M-96.4% | $18.12M+742% | $9.07M+1,325% | ||
| -$56.31M-19.3% | -$92.72M-16.9% | -$59.61M+11.0% | -$113.98M+2.0% | -$47.2M+71.0% | ||
| -15.5%+6.7pp | -29.8%+28.0pp | -18.6%+46.3pp | -39.7%+147pp | -22.2%+1,088pp | ||
| $7.94M+143% | $7.82M+137% | $8.3M+137% | $7.45M+103% | $3.26M-10.7% | ||
| -$795K-1,793% | -$2.09M— | -$128K— | -$293K— | -$42K— | ||
| -$57.94M-37.0% | -$94.39M-28.9% | -$58.58M+1.4% | -$114.19M-6.8% | -$42.28M+72.2% | ||
| -15.9%+4.0pp | -30.3%+23.0pp | -18.2%+39.3pp | -39.8%+132pp | -19.9%+1,018pp | ||
| -$1.99-4.7% | -$3.25+2.1% | -$2.53+2.3% | -$5.08-3.3% | -$1.90+73.2% | ||
| -$55.93M-19.4% | -$92.34M-17.0% | -$59.22M+11.1% | -$113.62M+2.1% | -$46.83M+71.1% | ||
| -15.4%+6.7pp | -29.7%+27.9pp | -18.4%+46.0pp | -39.6%+147pp | -22%+1,087pp | ||
| -$56.31M-19.3% | -$92.72M-16.9% | -$59.61M+11.0% | -$113.98M+2.0% | -$47.2M+71.0% |
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.3B in revenue over the trailing twelve months, up 149.0% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $325.1M over the trailing twelve months, a -25.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -25.1%, with a -25.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-12.85.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
